The gabapentinoids gabapentin and pregabalin have been related to addiction citing pharmacovigilance data, some case presentations and increasing reports mainly from methadone maintenance treatment programs or emergency medicine. Most of these reports were based on patients with another current or previous substance use disorder (SUD) 
INTRODUCTION
In the past ten years, there have been increasing reports linking gabapentin and pregabalin to abuse and dependence, life-threatening intoxications and death (Schifano et 
PHARMACOLOGY OF GABAPENTINOIDS
Pregabalin and gabapentin are approved pharmaceuticals for the treatment of some epileptic and pain disorders, and pregabalin also for generalized anxiety disorder (Bockabader et al. 2010 , Calandre et al. 2016 ). Pharmacologically, both drugs are very closely related (Bockbader et al. 2010 , Calandre et al. 2016 ). Therefore, gabapentin and pregabalin can be placed in own group of gabapentinoids (Rogawski & Bazil 2008) . They are 3-substituted derivatives of the neurotransmitter -aminobutyric acid (GABA) and known inhibitors of 2 -subunit-containing voltage-dependent calcium channels (VGCC). These special VGCCs are predominantly located in presynaptic membranes, and gabapentinoids were shown to restrain stimulus-dependent synaptic transmitter release, chiefly the excitatory transmitter glutamate and norepinephrine, but not dopamine (Dooley et al. 2000 , Bockbader et al. 2010 , Rogawski & Bazil 2008 . There by, gabapentinoids may act against aberrant neuronal excitation and, possibly, also against sensitization (Eroglu et al. 2009 ). Additionally, therapeutic doses of gabapentinoids are dose dependently associated with a modest increase of the extracellular GABA-concentration also in the human brain cortex (Bockbader et al. 2010 , Cai et al. 2012 , Calandre et al. 2016 ) and, thus, have weak GABAmimetic features that most likely drive the relaxation and euphoria which are often experienced in the beginning of the gabapentinoid use or therapy and after overdoses. There is a substantial tolerance against this "euphoric high" being typical for traditional GABAmimetics, e.g. benzodiazepines or propofol (Bonnet 2011). Pharmacokinetically, the gabapentinoids are nearly "ideal" pharmaceuticals with negligible interaction potential (with the exception of combining with clozapine or opioids (Englisch et al. 2012, Calandre et al. 2016)), no metabolism and no protein binding (Bockbader et al. 2010 , Calandre et al. 2016 ). However, they need a dose reduction alongside increasing renal insufficiency (Calandre et al. 2016 ). In comparison with propofol and benzodiazepines, gabapentinoids were the safest GABAmimetics with a wide dose range between pleasure (euphoria) and death due to overdoses. Whether an extreme oral overdose of gabapentin is sufficient enough to induce life threatening respiratory or cardiac insufficiency in otherwise healthy nonelderly subjects is still controversial (Verma et al. 1999 , Batoon et al. 2001 , Ongley et al. 2014 ). However, an excessive overdose of pregabalin may have fatal consequences if combined with opioid therapy and probably also with sedative therapy (Häkkinen et al. 2014) . Fatalities in association with excessive gabapentin use alone have not yet become known, although gabapentin has been assumed to be the operative agent of two suicides (Middleton 2011 , Cantrell et al. 2015 . Suicides by pregabalin alone have not yet been described, but vice versa, suicidal ideations have been reported after initiating a gabapentinoid therapy (Mutschler et al. 2011 ) which have also been described for other anticonvulsants (Mula et al. 2013 ). There are further important pharmacologic differences between gabapentin and pregabalin. Firstly, gabapentin is absorbed more slowly and has a lower bioavailability (33-66% for gabapentin vs >90% for pregabalin). Secondly, gabapentin`s plasma concentrations have been found to have a non-linear relationship with increasing oral doses. In the case of pregabalin, the plasma concentrations increase more rapidly and linearly with increasing doses if compared with gabapentin. Thirdly, pregabalin has a stronger inhibitory action on the 2 -subunits containing VCGGs than gabapentin (Bockbader et al. 2010 , Calandre et al. 2016 ).
WIDE DISTRIBUTION OF GABAPENTINOIDS
Since their introduction into the markets (gabapentin 1997, pregabalin 2004), both gabapentinoids have become blockbuster prescription drugs with meanwhile myriads of prescriptions worldwide (Kapil et 
ANALYZING CASE REPORTS ABOUT GABAPENTINOID ADDICTION
The authors are familiar with gabapentin prescriptions since the late 1990ies (Bonnet et al. 1999 ) and used gabapentin also "off-label" temporarily and beneficially over thousand times i) as an adjunct in the treatment of withdrawal symptoms due to alcohol, benzodiazepines, cannabis and opioids (Freynhagen et al. 2016) or ii) in the treatment of nervousness or agitation in anxiety and affective disorders or dementia (Bonnet & Scherbaum 2016). Among those patients with no relation to another SUD (except for nicotine dependence), we saw 6 cases of mid-life adults and elderlies, who developed a withdrawal syndrome after several weeks of the treatment with gabapentin. These patients (4 females, 2 males) had been diagnosed with generalized anxiety disorder or anxious depression and had stopped the gabapentin treatment (1200-3200 mg gabapentin/day) erroneously in an abrupt manner. Upcoming withdrawal symptoms resembled those of SSRIs (Fava et al. 2015) or benzodiazepines (Tyrer et al. 1990 ) and comprised of agitation, dysphoria, irritability, depersonalization, gait instability, vertigo, lightheadness, dizziness, fatigue, tremor, insomnia, myalgia, flu-like symptoms, abdominal discomfort, nausea, sleeplessness, palpitations and tachycardia. The larger the gabapentin doses had been prior to abrupt quitting, the stronger was the withdrawal syndrome, which could be well mitigated by reinstating gabapentin, which was thereafter gradually tapered in the following few weeks without problems. With the exception of this withdrawal syndrome and some tolerance to gabapentin's intended beneficial action on agitation and anxiety, there were no further symptoms of SUD in these patients, especially no reward craving, no loss of control, no drug-seeking behavior or further narrowed behaviors toward this drug -all these symptoms would have been typical for behavioral (psychological 
OTHER CLINICAL OBSERVATIONS ABOUT GABAPENTINOID ADDICTION
In clinical populations, gabapentin misuse and overdosing was identified most often in association with opiate addiction and multiple drug using (Bastiaens et al. 2016 , Wilens et al. 2015 , Baird et al. 2013 . In support, a prospective study in Appalachian Kentucky found a large increase of gabapentin use in the cohort of non-medical prescription opioid users, who used gabapentin specifically to get "high" (Smith et al. 2015 ). An amplification of a desired opioid high and relief of anxiety symptoms during opiate withdrawal were strong factors for promoting this misuse 
ADDICTIVE USE OF GABAPENTINOIDS IN VARIOUS POPULATIONS

LIKING AND WANTING OF GABAPENTINOIDS
Unlike traditional psychoactive drugs, there is less, if any, evidence for gabapentinoids to be misused in a long-term manner (Smith et On this background, we do suggest that gabapentin and pregabalin belong to such substances, which themselves have no relevant addiction potency suis generis ("wanting"), but could become addictive in patients with prior SUD-experience. Those patients look for various options broadly being able to induce euphoria and to improve their affected stress reactivity that occur following substance addiction (Fosnocht & Brand 2016). Unlike nicotine, alcohol, opiates or benzodiazepines,
there is yet no evidence for gabapentinoids to facilitate the misuse of other drugs in patients without a history of SUD.
Although gabapentinoids are widely distributed, we have found only 4 cases (as mentioned above) supporting a "wanting" of gabapentinoids in patients without a history of SUD and these 4 cases refer to pregabalin and not to gabapentin (Yargic & 
EVALUATING THE ADDICTIVE POWER OF GABAPENTINOIDS
Weighting the adverse effects being published in association with gabapentin and pregabalin and considering the information about their addictive power as mentioned above, we propose Table 1 to compare the abuse potential and toxicity of gabapentinoids with those of traditional psychoactive substances. As yet, pregabalin deemed more risky to induce dependence than gabapentin. Most likely, this is primarily based upon the special pharmacokinetic feature that unlike gabapentin, the plasma (and brain) concentrations of 
CONCLUSION
Altogether, we support the view that the abuse potential of both, gabapentin and pregabalin, is of lower priority in patients without another current or past SUD. In these "abuse-history-free" patients, the treatment with gabapentinoids is advised to be managed similar to the treatment with other frequently prescribed medications. In patients with a history of SUD, however, gabapentinoids (notably pregabalin) should better to be avoided or if indispensable, administered with caution by using a strict therapeutic and prescription monitoring. This is already stated in the package inserts of gabapentinoid medications. Prospective studies comparing the frequency, pattern and course of addiction criteria (Dilling & Freyberger 2006 , APA 2013 ) and drug safety data alongside the gabapentinoid use or misuse of patients with and without the experience of another SUD are missing and warranted to estimate the true addictive and hazardous potency of gabapentin and pregabalin more accurately which is also recommended for the antidepressants, antipsychotics and non-opiod pain relievers being supposed to be addictive. 
